**HSV 2 IgA**

**1399-11**

<table>
<thead>
<tr>
<th>Test</th>
<th>HSV 2 IgA ELISA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method</td>
<td>ELISA: Enzyme Linked Immunosorbent Assay</td>
</tr>
<tr>
<td>Principle</td>
<td>Indirect: Antigen Coated Plate</td>
</tr>
<tr>
<td>Detection Range</td>
<td>Qualitative Positive; Negative control &amp; Cut off</td>
</tr>
<tr>
<td>Sample</td>
<td>5ul Serum</td>
</tr>
<tr>
<td>Total Time</td>
<td>~ 75 min</td>
</tr>
<tr>
<td>Shelf Life</td>
<td>12 Months from the manufacturing date</td>
</tr>
</tbody>
</table>

*Laboratory results can never be the only base of a medical report. The patient history and further tests have to be taken into account*
NAME AND INTENDED USE
The Diagnostic Automation, Inc. ELISA, HSV 2 IgA is intended for the detection of IgA antibodies to herpes simplex virus 2 (HSV 2).

SUMMARY AND EXPLANATION OF THE TEST
Herpes Simplex Virus is a common pathogen and its primary infection is usually asymptomatic. There are two immunologically distinct types of HSV: Type 1 and Type 2. HSV 1 is generally associated with oral infection and lesions above the waist, and HSV 2 is associated with genital infections and lesions below the waist. Clinical cases primarily are 1) eczema herpeticum with eczematous skin changes with numerous lesions, 2) Gingivo-stomatitis and 3) Herpes sepsis, almost only found in newly born of premature infants. The Diagnostic Automation, Inc. ELISA, HSV 2 IgA is an accurate serologic method to detect HSV specific antibody in serum sample.

PRINCIPLE OF THE TEST
Purified HSV antigen is coated on the surface of microwells. Diluted patient serum is added to wells, and the HSV 2 IgA specific antibody, if present, binds to the antigen. All unbound materials are washed away. After adding enzyme conjugate, it binds to the antibody-antigen complex. Excess enzyme conjugate is washed off and TMB Chromogenic substrate is added. The enzyme conjugate catalytic reaction is stopped at a specific time. The intensity of the color generated is proportional to the amount of IgA specific antibody in the sample. The results are read by a microwell reader compared in a parallel manner with calibrator and controls.

MATERIALS PROVIDED
1. Microwell Strips: purified HSV 2 antigen coated wells. (12 x 8 wells)
2. Sample Diluent: Blue Color Solution 1 vial (22 ml)
3. Calibrator. Factor value (f) stated on label. Red Cap. 1 vial (150 µl)
4. Negative Control: Range stated on label. Natural Cap 1 vial (150 µl)
5. Positive Control: Range stated on label. Brown Cap. 1 vial (150 µl)
6. Washing Concentrate 20x: 1 bottle (50 ml)
7. Enzyme Conjugate: Red color solution. 1 vial (12 ml)
8. TMB Chromogenic Substrate: Amber bottle. 1 vial (12 ml)
9. Stop Solution 1 vial (12 ml)

STORAGE AND STABILITY
1. Store the kit at 2 - 8 ºC.
2. Always keep microwells tightly sealed in pouch with desiccants. We recommend you use up all wells within 4 weeks after initial opening of the pouch.
3. The reagents are stable until expiration of the kit.
4. Do not expose test reagents to heat, sun or strong light during storage or usage.

WARNINGS AND PRECAUTIONS
1. Potential biohazardous materials:
   The calibrator and controls contain human source components which have been tested and found nonreactive for hepatitis B surface antigen as well as HIV antibody with FDA licensed reagents. However, as there is no test method that can offer complete assurance that HIV, Hepatitis B virus or other infectious agents are absent, these reagents should be handled at the Biosafety Level 2, as
recommended in the Centers for Disease Control/National Institutes of Health manual, "Biosafety in Microbiological and Biomedical Laboratories." 1984

2. Do not pipette by mouth. Do not smoke, eat, or drink in the areas in which specimens or kit reagents are handled.

3. The components in this kit are intended for use as an integral unit. The components of different lots should not be mixed.

4. This product contains components preserved with sodium azide. Sodium azide may react with lead and copper plumbing to form explosive metal azide. On disposal, flush with a large volume of water.

SPECIMEN COLLECTION AND HANDLING

1. Collect blood specimens and separate the serum.
2. Specimens may be refrigerated at 2 - 8 °C for up to seven days or frozen for up to six months. Avoid repetitive freezing and thawing of serum sample.

PREPARATION FOR ASSAY

1. Prepare 1x washing buffer. Prepare washing buffer by adding distilled or deionized water to 20 x wash concentrate to a final volume of 1 liter.
2. Bring all specimens and kit reagents to room temperature (20-25 °C) and gently mix.

ASSAY PROCEDURE

1. Place the desired number of coated strips into the holder.
2. Prepare 1:40 dilutions by adding 5 µl of the test samples, negative control, positive control, and calibrator to 200 µl of Sample Diluent. Mix well.
3. Dispense 100 µl of diluted sera, calibrator, and controls into the appropriate wells. For the reagent blank, dispense 100 µl Sample Diluent in 1A well position. Tap the holder to remove air bubbles from the liquid and mix well. Incubate for 30 minutes at room temperature.
4. Remove liquid from all wells and repeat washing three times with washing buffer.
5. Dispense 100 µl of enzyme conjugate to each well and incubate for 30 minutes at room temperature.
6. Remove enzyme conjugate from all wells. Repeat washing three times with washing buffer.
7. Dispense 100 µl of TMB Chromogenic Substrate to each well and incubate for 15 minutes at room temperature.
8. Add 100 µl of Stop Solution to stop reaction. Make sure there are no air bubbles in each well before reading.
9. Read O.D. at 450 nm with a microwell reader.

CALCULATION OF RESULTS

1. To obtain Cut off OD value: Multiply the OD of Calibrator by Factor (f) printed on label of Calibrator.
2. Calculate the IgA Index of each determination by dividing the OD values of each sample by obtained OD value of Cut off.

For example:

If Factor (f) value on label = 0.4

This factor (f) is a variable. It is specific for a lot manufactured and printed on label of Calibrator.

Obtained Calibrator O.D. = 1.100
Cut-off O.D. = 1.100 x 0.4 = 0.44 (By definition IgA Index = 1)
Patient sample O.D. = 0.580
IgA Index = 0.580 / 0.44 = 1.32 (Positive result)

Patient sample O.D. = 0.320
IgA Index = 0.320 / 0.44 = 0.73 (Negative result)

QUALITY CONTROL
The test run may be considered valid provided the following criteria are met:

1. The O.D. value of the reagent blank against air from a microwell reader should be less than 0.150.
2. If the O.D. value of the Calibrator is lower than 0.250, the test is not valid and must be repeated.
3. The HSV 2 A Index for Negative and Positive Control should be in the range stated on the labels.

INTERPRETATION
Negative: HSV 2 IgA Index of 0.90 or less are seronegative for IgA antibody to HSV 2.
Equivocal: HSV 2 IgA Index of 0.91-0.99 is equivocal. Sample should be retested.
Positive: HSV 2 IgA Index of 1.00 or greater are seropositive

PERFORMANCE CHARACTERISTICS
Precision:
The precision of the assay was evaluated by testing three different sera of eight replicates over a period of one week.
The intra-assay and inter-assay C.V. are summarized below:

<table>
<thead>
<tr>
<th></th>
<th>Negative</th>
<th>Low positive</th>
<th>Positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intra-assay</td>
<td>9.2%</td>
<td>8.6%</td>
<td>6.5%</td>
</tr>
<tr>
<td>Inter-assay</td>
<td>12.5%</td>
<td>10.7%</td>
<td>7.4%</td>
</tr>
</tbody>
</table>

LIMITATION OF THE PROCEDURE
1. As with other serological assays, the results of these assays should be used in conjunction with information available from clinical evaluation and other diagnostic procedures.

2. Samples obtained too early during primary infection may not contain detectable antibody.

3. A single serum sample should not be used to aid in the diagnosis of recent infection. Paired samples should be collected and tested simultaneously to look for seroconversion.

4. To prevent false negative results caused by the presence of specific IgG and rheumatoid factor (RF) in some specimens, reagents provided in this kit has been formulated to resolve these interferences. However, specimens with extremely high RF and high autoimmune antibodies, the possibility of these interferences cannot be ruled out entirely.

5. A negative serological test does not exclude the possibility of past infection. Following primary HSV infection, antibody may fall to undetectable levels and then be boosted by later clinical infection with the same or heterologous type. Such a phenomenon may lead to incorrect interpretations of seroconversion and primary infection, or negative antibody status. In addition, samples obtained too
early during primary infection may not contain detectable antibody. Some persons may fail to develop detectable antibody after Herpes infection.

REFERENCES

SUMMARY OF ASSAY PROCEDURE

<table>
<thead>
<tr>
<th>Step</th>
<th>(20-25°C Room temp.)</th>
<th>Volume</th>
<th>Incubation time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Sample dilution 1:40 = 5 µl / 200 µl</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Diluted sample &amp; controls</td>
<td>100 µl</td>
<td>30 minutes</td>
</tr>
<tr>
<td>3</td>
<td>Washing buffer (3 times)</td>
<td>350 µl</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Enzyme conjugate</td>
<td>100 µl</td>
<td>30 minutes</td>
</tr>
<tr>
<td>5</td>
<td>Washing buffer (3 times)</td>
<td>350 µl</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>TMB Chromogenic Substrate</td>
<td>100 µl</td>
<td>15 minutes</td>
</tr>
<tr>
<td>7</td>
<td>Stop solution</td>
<td>100 µl</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Reading OD 450 nm</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Date Adopted: 2017-05-12  
DAI-HSV2 IgA

---

DIAGNOSTIC AUTOMATION, INC.  
21250 Califa Street, Suite 102 and 116, Woodland Hills, California 91367 USA  
Tel: (818) 591-3030 Fax: (818) 591-8383  
ISO 13485-2003

Revision Date: 2017-05-11